Loading...
Market
Will Moderna's mRESVIA RSV Vaccine be approved by the EMA for adults 60+ by June 30, 2025?
2
Resolution / Starting Odds
Yes • 50%
No • 50%
Official announcements from the European Medicines Agency
Story
Moderna's mRESVIA RSV Vaccine Approved by Health Canada for Adults 60 and Older
Nov 8, 2024, 03:13 PM
Moderna has received approval from Health Canada for its respiratory syncytial virus (RSV) vaccine, mRESVIA, for adults aged 60 years and older. This marks the first mRNA-based vaccine for RSV to be authorized in Canada. The approval was announced on Friday, making it a significant milestone for the vaccine maker. The stock ticker for Moderna is $MRNA.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
